Market News & Trends
CPI Accelerates Gene Therapy Development With Robust Purification System
CPI recently announced the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra…
Foamix Receives FDA Approval for Topical Treatment
Foamix Pharmaceuticals Ltd. recently announced the US FDA has approved its novel AMZEEQ (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, is indicated for…
Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
Theralase Technologies Inc. recently announced the company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course. The patent,…
Genedata & Merck Co-Develop Digital Platform
Genedata recently announced the successful completion of a multi-year software development project in close collaboration with Merck, a leading science and technology company. Fulfilling Merck’s…
BD Launches Two-Step Disposable Autoinjector
BD (Becton, Dickinson and Company) recently announced the launch of the BD Intevia 1 mL two-step disposable autoinjector, a robust platform device combining autoinjector and…
CombiGene Signs Agreement With Cobra Biologics
CombiGene AB recently signed an agreement with the Anglo-Swedish Contract Development and Manufacturing Organisation (CDMO) Cobra Biologics (Cobra) for production of candidate drug CG01. The…
Adaptate Biotherapeutics Formed to Develop Antibody-Based Therapies That Modulate Gamma Delta T-Cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, recently announced the formation of a spin-out…
Yourway Mitigates Uncertainty of Brexit for Clinical Trials In Europe
Yourway, the only truly integrated premium courier and clinical packager in the industry, announced its establishment of a new location within the European Union providing…
Novavax Initiates Pivotal Phase 3 Clinical Trial
Novavax, Inc. recently announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged…
Orgenesis Announces Co-Development Agreement With Accellix
Orgenesis Inc recently announced it has entered into a co-development agreement with Accellix, Inc. The agreement will enable Orgenesis to integrate Accellix’s proprietary optic system, cartridges, reagents,…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….